FTC drops part of Elan investigation

Elan has said that US regulators have dropped part of an investigation into whether it tried to block unfairly a generic rival of Skelaxin, its muscle-relaxant medicine.

Elan has received a letter saying that the Federal Trade Commission is not to charge Elan for this.